Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

A role for BRCA1 in uterine leiomyosarcoma.

Xing D, Scangas G, Nitta M, He L, Xu X, Ioffe YJ, Aspuria PJ, Hedvat CY, Anderson ML, Oliva E, Karlan BY, Mohapatra G, Orsulic S.

Cancer Res. 2009 Nov 1;69(21):8231-5. doi: 10.1158/0008-5472.CAN-09-2543. Epub 2009 Oct 20.

2.

p53, epidermal growth factor, and platelet-derived growth factor in uterine leiomyosarcoma and leiomyomas.

Anderson SE, Nonaka D, Chuai S, Olshen AB, Chi D, Sabbatini P, Soslow RA.

Int J Gynecol Cancer. 2006 Mar-Apr;16(2):849-53.

PMID:
16681772
3.

Conditional inactivation of Brca1, p53 and Rb in mouse ovaries results in the development of leiomyosarcomas.

Clark-Knowles KV, Senterman MK, Collins O, Vanderhyden BC.

PLoS One. 2009 Dec 31;4(12):e8534. doi: 10.1371/journal.pone.0008534.

4.

Induction of ovarian leiomyosarcomas in mice by conditional inactivation of Brca1 and p53.

Quinn BA, Brake T, Hua X, Baxter-Jones K, Litwin S, Ellenson LH, Connolly DC.

PLoS One. 2009 Dec 31;4(12):e8404. doi: 10.1371/journal.pone.0008404.

5.

Dual targeting of mTOR and aurora-A kinase for the treatment of uterine Leiomyosarcoma.

Brewer Savannah KJ, Demicco EG, Lusby K, Ghadimi MP, Belousov R, Young E, Zhang Y, Huang KL, Lazar AJ, Hunt KK, Pollock RE, Creighton CJ, Anderson ML, Lev D.

Clin Cancer Res. 2012 Sep 1;18(17):4633-45. doi: 10.1158/1078-0432.CCR-12-0436. Epub 2012 Jul 20.

6.

Uterine leiomyosarcoma management, outcome, and associated molecular biomarkers: a single institution's experience.

Lusby K, Savannah KB, Demicco EG, Zhang Y, Ghadimi MP, Young ED, Colombo C, Lam R, Dogan TE, Hornick JL, Lazar AJ, Hunt KK, Anderson ML, Creighton CJ, Lev D, Pollock RE.

Ann Surg Oncol. 2013 Jul;20(7):2364-72. doi: 10.1245/s10434-012-2834-0. Epub 2013 Jan 20.

7.

Clinical outcomes and prognostic markers in uterine leiomyosarcoma: a population-based cohort.

Garcia C, Kubat JS, Fulton RS, Anthony AT, Combs M, Powell CB, Littell RD.

Int J Gynecol Cancer. 2015 May;25(4):622-8. doi: 10.1097/IGC.0000000000000370.

PMID:
25675041
8.

Retrospective cohort study evaluating the impact of intraperitoneal morcellation on outcomes of localized uterine leiomyosarcoma.

George S, Barysauskas C, Serrano C, Oduyebo T, Rauh-Hain JA, Del Carmen MG, Demetri GD, Muto MG.

Cancer. 2014 Oct 15;120(20):3154-8. doi: 10.1002/cncr.28844. Epub 2014 Jun 12.

9.

A rare case of uterine leiomyosarcoma metastasis to the duodenum.

Patel JK, Cervellione KL, Sulh M, Patel AA, Gintautas J.

Proc West Pharmacol Soc. 2009;52:8-10.

PMID:
22128409
10.

Loss of CDKN2A Promoter Methylation Coincides With the Epigenetic Transdifferentiation of Uterine Myosarcomatous Cells.

Roncati L, Barbolini G, Sartori G, Siopis E, Pusiol T, Maiorana A.

Int J Gynecol Pathol. 2016 Jul;35(4):309-15. doi: 10.1097/PGP.0000000000000181.

PMID:
27276112
11.

Uterine Leiomyosarcoma Tumorigenesis in Lmp2-deficient Mice: Involvement of Impaired Anti-oncogenic Factor IRF1.

Hayashi T, Horiuchi A, Sano K, Yaegashi N, Konishi I.

Anticancer Res. 2015 Sep;35(9):4665-79.

PMID:
26254356
12.

External validation of a prognostic nomogram for overall survival in women with uterine leiomyosarcoma.

Iasonos A, Keung EZ, Zivanovic O, Mancari R, Peiretti M, Nucci M, George S, Colombo N, Carinelli S, Hensley ML, Raut CP.

Cancer. 2013 May 15;119(10):1816-22. doi: 10.1002/cncr.27971. Epub 2013 Mar 1.

13.

Mammary tumor formation in p53- and BRCA1-deficient mice.

Cressman VL, Backlund DC, Hicks EM, Gowen LC, Godfrey V, Koller BH.

Cell Growth Differ. 1999 Jan;10(1):1-10.

14.

Let-7 repression leads to HMGA2 overexpression in uterine leiomyosarcoma.

Shi G, Perle MA, Mittal K, Chen H, Zou X, Narita M, Hernando E, Lee P, Wei JJ.

J Cell Mol Med. 2009 Sep;13(9B):3898-905. doi: 10.1111/j.1582-4934.2008.00541.x. Epub 2008 Oct 13.

15.

The role of adjuvant therapy in uterine leiomyosarcoma.

Ducie JA, Leitao MM Jr.

Expert Rev Anticancer Ther. 2016;16(1):45-55. doi: 10.1586/14737140.2016.1115724. Epub 2015 Nov 26. Review.

16.

Comparative immunohistochemical and molecular analysis of uterine and extrauterine leiomyosarcomas.

Rao UN, Finkelstein SD, Jones MW.

Mod Pathol. 1999 Nov;12(11):1001-9.

PMID:
10574596
17.

The value of re-exploration in patients with inadvertently morcellated uterine sarcoma.

Oduyebo T, Rauh-Hain AJ, Meserve EE, Seidman MA, Hinchcliff E, George S, Quade B, Nucci MR, Del Carmen MG, Muto MG.

Gynecol Oncol. 2014 Feb;132(2):360-5. doi: 10.1016/j.ygyno.2013.11.024. Epub 2013 Dec 1.

PMID:
24296345
18.

Multimodal treatment with doxorubicin, cisplatin, and ifosfamide for the treatment of advanced or metastatic uterine leiomyosarcoma: a unicentric experience.

Hadoux J, Rey A, Duvillard P, Lhommé C, Balleyguier C, Haie-Meder C, Morice P, Tazi Y, Leary A, Larue C, Pautier P.

Int J Gynecol Cancer. 2015 Feb;25(2):296-302. doi: 10.1097/IGC.0000000000000344.

PMID:
25581897
19.

The influence of primary site on outcomes in leiomyosarcoma: a review of clinicopathologic differences between uterine and extrauterine disease.

Farid M, Ong WS, Tan MH, Foo LS, Lim YK, Chia WK, Soh LT, Poon D, Lee MJ, Ho ZC, Jeevan R, Chin F, Teo M, Quek R.

Am J Clin Oncol. 2013 Aug;36(4):368-74. doi: 10.1097/COC.0b013e318248dbf4.

PMID:
22772425
20.

Deficiency in p53 but not retinoblastoma induces the transformation of mesenchymal stem cells in vitro and initiates leiomyosarcoma in vivo.

Rubio R, García-Castro J, Gutiérrez-Aranda I, Paramio J, Santos M, Catalina P, Leone PE, Menendez P, Rodríguez R.

Cancer Res. 2010 May 15;70(10):4185-94. doi: 10.1158/0008-5472.CAN-09-4640. Epub 2010 May 4.

Supplemental Content

Support Center